登录

Optomedic Raises Announces Close Of ¥100 Million Series D Financing Round

作者: Mailman 2021-07-22 09:16
欧谱曼迪
http://www.optomedic.com
企业数据由 动脉橙 提供支持
高端光学医疗器械研发商 | 战略融资 | 运营中
中国-广东
2023-12-31
融资金额:数千万人民币
信达鲲鹏
查看

(VCBeat) July. 15, 2021 -- Guangdong OptoMedic Technologies Inc. ("Optomedic") recently announced the close of a ¥100 million Series A investment round,jointly led by Primavera Capital and SDIC CMC Investment. Haoyue Capital acted as the exclusive financial adviser. In July 2020, OptoMedic launched the world's first 4K fluorescence-guided laparoscopic system, marking that the company's independently developed fluorescent navigation endoscope has reached the world's leading level. The successful completion of this round reflects the capital market's recognition of and expectation for the future development of OptoMedic in the field of functional endoscopy.


OptoMedic is a high-tech company committed to providing high-performance medical devices and services utilizing cutting-edge optical and bio-optical technologies in the medical field.


OptoMedic was founded in July 2013 by a coalition of multidisciplinary experts in medical, biomedical, engineering, quality assurance as well as regulatory affairs. Dedicated to technological innovations, it provides its customers with an array of high-end medical devices, among which the intraoperative endoscopic fluorescence navigation system has become a global leader and has been widely used across many departments in general surgery.


OptoMedic's product line covers white light/fluorescence navigation system, soft lens system, disposable lens system, as well as supporting equipment, fluorescent developer, etc. With the leading technology and excellent cost performance, OptoMedic has been widely recognized by users. Nearly one-third of the top 100 first-class hospitals at grade 3in China have purchased the products of OptoMedic, and the domestic market share of its fluorescent navigation endoscopes is nearly 50%.


>>>>

About Primavera Capital


Deeply rooted in China with a global vision and connectivity, Primavera Capital manages both RMB and USD funds for leading institutions, corporations and families around the world and contribute to their investment objectives. The company invests across the full life cycle of a business, from early-stage venture funding to late-stage growth capital, restructuring financing, carve-out/ spin-off, and full buyout.


As of 2020, Primavera Capital has invested in over 60 portfolio companies, including some of the largest, most influential, and most innovative businesses in the world.


>>>>

About SDIC CMC Investment


SDIC CMC Investment is a professional private equity management company jointly set up by SDIC and China Merchants Capital. The company mainly invests in the fields of intelligent manufacturing, new energy intelligent vehicles, life science, information and communication technology and others. SDIC CMC Investment is committed to promoting the green, digital and service-oriented development of the manufacturing industry, with an AUM of more than RMB100 billion.

相关赛道 医学影像
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

牙科生物技术公司Calcivis完成450万英镑股权融资,推动CALCIVIS成像系统上市

【首发】西山科技完成过亿元D轮融资,产业投资人助力打造国际顶尖微创医疗器械品牌

Meio CadiNav Medical Completes Pre-Series A Financing

Well-healthcare Raises ¥100 Million in Extended Series A Round

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

13万产品远销全球超80个国家,Occlutech“织”出一条封堵器产品线

2021-07-22
下一篇

Xinwen Biotech Closes ¥10 Million Angel Financing

2021-07-22